NDA 207155 · Acrotech Biopharma
Evomela
Melphalan Hydrochloride · Intravenous
OrphanLast checked: Nov 19, 2026Latest source record: Apr 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 10, 2016
Approved uses
2
Original approval plus efficacy supplements
Registered trials
903
155 Phase 3, 91 recruiting
FAERS reports
22,969
22,377 serious, 5,247 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE BONE MARROW SUPPRESSION, HYPERSENSITIVITY, and LEUKEMOGENICITY Severe bone marrow suppression with resulting infection or bleeding may occur. Controlled trials comparing intravenous (IV) melphalan to oral melphalan have shown more myelosuppression with the IV formulation. Monitor hematologic laboratory parameters. [see Warnings and Precautions ( 5.1 )] Hypersensitivity reactions, including anaphylaxis, have occurred in approximately 2% of patients who received the IV formulation of melphalan. Discontinue treatment with Evomela for serious hypersensitivity reactions. [see Warnings and Precautions ( 5.4 )] Melphalan produces chromosomal aberrations in vitro and in vivo. Evomela should be considered potentially leukemogenic in humans. [see Warnings and Precautions ( 5.5 )] WARNING: SEVERE BONE MARROW SUPPRESSION, HYPERSENSITIVITY, AND LEUKEMOGENICITY See full prescribing...
What it is approved for
From the label in effect Sep 15, 2026.
Evomela is an alkylating drug indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma. ( 1.1 ) 1.1 Multiple Myeloma-Conditioning Treatment Evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma.
Mechanism: Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N 7 position of guanine. Like other bifunctional alkylating agents, it is active against both resting and rapidly dividing tumor cells.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 10, 2016 Original approval · Efficacy Review
- Mar 10, 2016 Original approval · Type 5 - New Formulation or New Manufacturer OrphanReviewLabelLetter
1 products under this application
- EVOMELA · MELPHALAN HYDROCHLORIDE EQ 50MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Melphalan" as an intervention, any sponsor and status, largest first.
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsPivotal-lookingStatus unknown
University of LeedsAcademic, hospital or other
NCT01554852 · 4,420 participants · Start May 2010 · Primary completion Dec 2021
Drug: Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen; Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen and 7 more · For: Multiple Myeloma
Sites: United Kingdom, United Kingdom
- High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)Pivotal-lookingCompleted
St. Anna KinderkrebsforschungAcademic, hospital or other
NCT01704716 · 3,569 participants · Start Feb 1, 2002 · Primary completion Jan 30, 2025
Drug: Vincristine; Aldesleukin and 9 more · For: Neuroblastoma
Sites: Newcastle, Australia; Sydney, Australia; Vienna, Austria · 122 sites in all
Oslo University HospitalAcademic, hospital or other
NCT04817956 · 3,000 participants (planned) · Start Apr 1, 2021 · Primary completion Mar 30, 2040
Drug: Atezolizumab · For: Cancer Metastatic
Sites: Ålesund, Norway; Bergen, Norway; Bodø, Norway · 17 sites in all
National Cancer Institute (NCI)NIH
NCT05564390 · 2,000 participants (planned) · Start Jun 18, 2024 · Primary completion May 15, 2029
Drug: Azacitidine; Azacitidine and 18 more · For: Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm; Acute Myeloid Leukemia Post Cytotoxic Therapy and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 360 sites in all
- Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPivotal-lookingCompleted
The University of New South WalesAcademic, hospital or other
NCT00454480 · 2,000 participants (planned) · Start Aug 2006 · Primary completion Aug 2012
Drug: alemtuzumab; arsenic trioxide and 9 more · For: Leukemia; Myelodysplastic Syndromes
Sites: Basingstoke, United Kingdom; Bath, United Kingdom; Birmingham, United Kingdom · 96 sites in all
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaPivotal-lookingCompleted
CelgeneBristol Myers Squibb (BMY)
NCT00689936 · 1,623 participants · Start Aug 21, 2008 · Primary completion Jul 14, 2016
Drug: Lenalidomide and low-dose dexamethasone; Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles and 1 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 288 sites in all
- Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple MyelomaPivotal-lookingCompleted
Stichting Hemato-Oncologie voor Volwassenen NederlandAcademic, hospital or other
NCT01208766 · 1,503 participants · Start Jan 2011 · Primary completion Dec 2020
Drug: Bortezomib, Melphalan, Prednisone (VMP); 1 or 2 cycle(s) HDM (High Dose Melphalan) and 1 more · For: Multiple Myeloma
Sites: Brisbane, Australia; Canberra, Australia; Melbourne, Australia · 208 sites in all
- Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaPivotal-lookingStatus unknown
University of LeicesterAcademic, hospital or other
NCT00020566 · 1,200 participants (planned) · Start Feb 2001 · Primary completion Dec 2011
Drug: dactinomycin; busulfan and 5 more · For: Sarcoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 103 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,484
- drug ineffective1,400
- plasma cell myeloma1,286
- febrile neutropenia1,255
- mucosal inflammation1,148
- neutropenia1,124
- pyrexia1,071
- pneumonia1,066
- thrombocytopenia1,048
- diarrhoea1,016
- product use in unapproved indication929
- sepsis809
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 156 |
| 2005 | 324 |
| 2006 | 216 |
| 2007 | 211 |
| 2008 | 320 |
| 2009 | 369 |
| 2010 | 181 |
| 2011 | 531 |
| 2012 | 458 |
| 2013 | 772 |
| 2014 | 898 |
| 2015 | 1,161 |
| 2016 | 1,184 |
| 2017 | 1,236 |
| 2018 | 1,681 |
| 2019 | 1,868 |
| 2020 | 1,937 |
| 2021 | 1,961 |
| 2022 | 1,538 |
| 2023 | 1,964 |
| 2024 | 1,736 |
| 2025 | 1,262 |
| 2026 | 1,005 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Evomela (Melphalan HCL/Betadex Sbes) · HCPCS J9246
2024 spending
$646K
Beneficiaries
137
147 claims
Per beneficiary
$4,712
2024 ASP limit $16.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $367,602 |
| 2021 | $415,076 |
| 2022 | $612,418 |
| 2023 | $660,795 |
| 2024 | $645,527 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
Park JR, Kreissman SG, London WB, et al. · JAMA 2019 · Comparative Study, Multicenter Study
- High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.
Lahuerta JJ, San-Miguel J, Jiménez-Ubieto A, et al. · Blood 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Myeloma, melphalan, and meta-analysis.
Bergsagel DE · J Clin Oncol 1992 · Comment, Editorial
- Phase 1/2 trial of Evomela for autologous transplant in myeloma: schedule optimization and matched comparison with MEL200.
Bashir Q, Thall PF, Kawedia JD, et al. · Blood Adv 2026 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Comparative Study
- Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.
Farag S, Bacher U, Jeker B, et al. · Bone Marrow Transplant 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
Sponsor: Acrotech Biopharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.